WATERTOWN, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic ...
WATERTOWN, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic ...
Selecta Biosciences Inc SELB provided an update on its ongoing strategic initiative to maximize stockholder value related to its economic interests in SEL-212, which is being developed for the ...
· Strategic licensing agreement for SEL-212, a unique phase 3-ready therapy powered by Selecta's breakthrough immune tolerance platform, ImmTOR™, with the potential to fulfil a significant unmet need ...
Selecta Biosciences' CEO referenced the "current market environment" when explaining the company's restructuring. (HAKINMHAN/iStock/Getty Images Plus) An analyst has reiterated that Selecta ...
Selecta Biosciences and Ginkgo Bioworks are extending their alliance to cover gene therapy delivery. Just months after disclosing a rare disease pact, the partners have unwrapped a second deal focused ...
WATERTOWN, Mass. and STOCKHOLM, Sweden, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI), today announced topline ...
Selecta Biosciences, Inc. (NASDAQ: SELB) (the Company) today announced that it has merged with Cartesian Therapeutics, Inc., a clinical-stage biotechnology company pioneering RNA cell therapies for ...
(RTTNews) - Selecta Biosciences Inc. (SELB) expects topline data from the Phase 3 DISSOLVE clinical program investigating SEL-212 in chronic refractory gout in the first-quarter of 2023. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results